Description
The BuyandBill.com Retina Report is published quarterly and provides an overview of pricing trends and pipeline information for ophthalmology drugs. Our focus is on drugs that treat wet age-related macular degeneration and geographic atrophy as well as intraocular steroids and other ophthalmology products. A high degree of importance is placed on the aflibercept and ranibizumab biosimilar classes.
Overview
The Q1 2026 Retina Report by BuyandBill.com offers an analysis of drug pricing and pipeline developments for office-administered ophthalmology treatments. The report places emphasis on therapies for wet age-related macular degeneration (wet AMD), geographic atrophy (GA), intraocular steroids, and a range of miscellaneous ophthalmic agents. It details current HCPCS codes, ASP (Average Sales Price), WAC (Wholesale Acquisition Cost), and ASP-to-WAC ratios, which help stakeholders assess discounting and reimbursement dynamics. The Retina Report also highlights the importance of tracking quarterly ASP fluctuations, given their direct impact on Medicare and commercial payer reimbursement.
We identify significant price erosion within the ranibizumab product class (Lucentis, Cimerli, and Byooviz), driven by increased biosimilar competition, with ASPs for some products declining over 50% in a single quarter. The aflibercept category is also experiencing disruption with the launch of biosimilars like Pavblu, which debuted in April 2025. Detailed treatment-level and annual pricing are presented for each product based on dosing schedules, revealing variability depending on indication and administration frequency. The ASP/WAC ratios for new and established drugs indicate varied discounting practices, with newer entries like geographic atrophy treatments (Syfovre, Izervay) showing minimal discounting thus far.
The Retina Report outlines the current ophthalmology drug pipeline, focusing on products from Phase 1 through the BLA/ANDA filing stages. This includes a growing number of aflibercept and ranibizumab biosimilars, as well as novel candidates for wet AMD, DME, diabetic retinopathy, uveitis, and GA.
